Αποτελέσματα Αναζήτησης
19 Απρ 2022 · A special technique called immunohistochemistry (IHC) is used to identify CD20 and determine whether an abnormal cancerous white blood cell (lymphocyte in particular) is a B-cell or T-cell.
CD20 on B Cells, Blood. Useful For. Evaluation of patients with a suspected CD19 deficiency (humoral immunodeficiency) Confirming complete absence of B cells in suspected primary humoral immunodeficiencies using both CD19 and CD20 markers.
One of the new topics in applying PET scans to the treatment of patients with diffuse large B-cell lymphoma is the use of early, or interim, scans to predict treatment outcome after only 1 to 3 cycles of treatment. Some studies, 50,51 but not all, 52,53 have found a dramatic impact on eventual treatment outcome.
CD20 Cell Expression Evaluation, Varies. Detecting cell-surface antigens on malignant cells that are potential therapeutic antibody targets, specifically CD20. Determining the eligibility of patients for monoclonal antibody therapies. Monitoring response to the therapeutic antibody.
Bone scan. Brachytherapy. BRCA gene test. Breast biopsy. Breast cancer risk assessment. Breast cancer supportive therapy and survivorship. Breast cancer surgery. Breast MRI. Breast reconstruction with flap surgery.
24 Οκτ 2019 · Advances in colorectal cancer screening. Mayo Clinic physicians John B. Kisiel, M.D., and David W. Larson, M.D., M.B.A., discuss the latest advancements in colorectal cancer screening, as well as the latest surgical techniques available for people with colorectal cancer.
9 Νοε 2020 · The outlook for patients with CD20-positive B-cell malignancies improved in the 1990s with the introduction of targeted therapy with the recombinant chimeric murine/human type I anti-CD20 monoclonal antibody (mAb) rituximab (RITUXAN®/MABTHERA®) [Citation 7, Citation 8].
